Abstracts tagged "interstitial lung disease and systemic sclerosis"

Abstract Number: 799 • 2018 ACR/ARHP Annual Meeting
Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database
Anna-Maria Hoffmann-Vold¹, Yannick Allanore², Margarida Alves³, Nicole Graf⁴, Paolo Airò⁵, Lidia Ananyeva⁶, László Czirják⁷, Serena Guiducci⁸, Eric Hachulla⁹, Mengtao Li¹⁰, Carina Mihai¹¹, Petros Sfikakis¹², Gabriele Valentini¹³, Otylia Kowal-Bielecka¹⁴ and Oliver Distler¹¹, ¹Oslo University Hospital, Oslo, Norway, ²Service de Rhumatologie A, Hôpital Cochin, Paris, France, ³Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland, ⁵UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, ⁶VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, ⁷Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ⁸Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Firenze, Italy, ⁹Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ¹⁰Department of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, ¹¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, ¹³Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, ¹⁴Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
Background/Purpose: Systemic sclerosis (SSc) carries a high risk for interstitial lung disease (ILD). Patients with SSc-ILD are prone to develop progressive lung fibrosis, but there…
Abstract Number: 2155 • 2018 ACR/ARHP Annual Meeting
Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink
Alicia Gayle¹, Nils Schoof², Margarida Alves², Deborah Clarke³, Chris Poole¹, Christina Raabe², Prithwiraj Das¹ and Toby Maher⁴, ¹Boehringer Ingelheim Ltd., Bracknell, United Kingdom, ²Boehringer Ingelheim International GmbH, Ingelheim, Germany, ³Department of Medical Affairs, Boehringer Ingelheim Ltd., Bracknell, United Kingdom, ⁴University College London and Royal Brompton Hospital, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease that is characterised by fibroblast dysfunction and excess extracellular matrix deposition that leads to skin thickening and…
Abstract Number: 2697 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis
Hiraku Suga¹, Ai Kuzumi¹, Yoshihide Asano¹, Ayumi Yoshizaki¹ and Shinichi Sato², ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²The University of Tokyo, Department of Dermatology, Tokyo, Japan
Background/Purpose: Interleukin (IL)-34 is a hematopoietic cytokine, which promotes survival, proliferation, and differentiation of monocytes and macrophages. We investigated serum IL-34 levels in patients with…
Abstract Number: 2713 • 2018 ACR/ARHP Annual Meeting
Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
Sabrina Hoa¹, Sasha Bernatsky², Russell Steele³ and Marie Hudson¹, ¹Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Immunosuppression is used to treat ILD, but little is known about its…
Abstract Number: 30 • 2018 ACR/ARHP Annual Meeting
CD21lo Cells Are Increased in Patients with Systemic Sclerosis and May be Associated with Interstitial Lung Disease
Erin Wilfong¹, Katherine Vowell², Leslie Crofford³ and Peggy Kendall¹, ¹Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic sclerosis (SSc) is a severe systemic disease characterized by fibrosis of the skin and visceral organs. While the exact pathogenesis of SSc is…
Abstract Number: 31 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Satoshi Ebata¹, Ayumi Yoshizaki², Takemichi Fukasawa¹, Kouki Nakamura¹, Maiko Hirakawa¹, Takashi Yamashita¹, Shunsuke Miura³, Ryosuke Saigusa¹, Megumi Hirabayashi¹, Asako Yoshizaki¹, Kaname Akamata¹, Yoshihide Asano⁴, Yutaka Kazoe⁵, Kazuma Mawatari⁵, Takehiko Kitamori⁵ and Shinichi Sato⁶, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁵Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁶Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of several organs. SSc-associated interstitial lung disease (ILD) is a frequent and severe complication…
Abstract Number: 731 • 2017 ACR/ARHP Annual Meeting
Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis
Wanlong Wu¹, Suzana Jordan², Mike Oliver Becker³, Rucsandra Dobrota³, Shuang Ye⁴, Britta Maurer⁵ and Oliver Distler², ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich; Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁵Department of Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: No data are available to distinguish between progressive and stable patients when mild lung fibrosis is diagnosed in systemic sclerosis (SSc) patients. This study…
Abstract Number: 752 • 2017 ACR/ARHP Annual Meeting
Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
Els Vandecasteele¹, Karin Melsens², Filip De Keyser³, Michel De Pauw⁴, Ellen Deschepper⁵, Saskia Decuman⁶, Yves Piette², Kristof Thevissen⁷, Guy Brusselle⁸ and Vanessa Smith³, ¹Dep of Cardiology, University Hospital Ghent, Ghent, Belgium, ²Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, Ghent, Belgium, ³Ghent University, Department of Internal Medicine, Ghent, Belgium, Ghent, Belgium, ⁴Dep of cardiology, University Hospital Ghent, Ghent, Belgium, ⁵Biostatistics Unit, UGent, Ghent, Belgium, ⁶Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Gent University, Gent, Belgium
TitleRole of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution. Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading…
Abstract Number: 1677 • 2017 ACR/ARHP Annual Meeting
Low Baseline Impedance in Proximal Esophagus and Decreased Pspw Index May Related with Pathogenesis of Interstitial Lung Disease in Systemic Sclerosis
Yunseok Kim¹, Hyun-Sook Kim², Joon Seong Lee¹ and Jung Ran Choi³, ¹Internal medicine, Soonchunhyang university Seoul hospital, Seoul, Korea, Republic of (South), ²Soonchenhyang university school of medicine, Seoul, Korea, Republic of (South), ³Department of Internal Medicine, Pohang St. Mary Hospital, Pohang, Korea, Republic of (South)
Background/Purpose: Interstitial lung disease (ILD) is a common but fatal complication of systemic sclerosis (SSc). Gastroesophageal reflux disease (GERD) may be related to pathogenesis of…
Abstract Number: 1696 • 2017 ACR/ARHP Annual Meeting
Performance of Forced Vital Capacity and Lung Diffusion Cut-Points for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann², Gerald W. Rouleau³, David Aaby⁴, Julia (Jungwha) Lee⁵, Carrie Richardson⁶, Jane Dematte⁷, Rishi Agrawal⁸, Rowland W. Chang⁹ and Monique Hinchcliff¹⁰, ¹Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Department of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Pulmonology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Forced vital capacity (FVC) and carbon monoxide diffusion (DLCO) are used to screen for systemic sclerosis associated interstitial lung disease (SSc-ILD). The purpose of…
Abstract Number: 853 • 2016 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis
John Pauling^1,2, Hui Lu¹, Zoe Betteridge^1,2, Gloria Salazar³, Shervin Assassi³, Maureen D Mayes³ and Neil J. McHugh^1,4, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies can be characterized in up to 95% of patients with systemic sclerosis (SSc) and provide enormous diagnostic and prognostic value in the clinical…
Abstract Number: 1872 • 2016 ACR/ARHP Annual Meeting
The Effect of Cyclophosphamide on Pulmonary Function and Dependence on Disease Activity of Interstitial Lung Disease Associated with Systemic Sclerosis
WMT van den Hombergh¹, E. Teesselink¹, HKA Knaapen-Hans¹, FHJ van den Hoogen², S.O. Simons³, J. Fransen⁴ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboudumc, Nijmegen, Netherlands, ³Respiratory Medicine, Radboud University Medical Centre, Nijmegen, Netherlands, ⁴Department of Rheumatolgy, Radboudumc Nijmegen, Nijmegen, Netherlands
THE EFFECT OF CYCLOPHOSPHAMIDE ON PULMONARY FUNCTION AND DEPENDENCE ON DISEASE ACTIVITY OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS W. M. T. Van Den…
Abstract Number: 3245 • 2016 ACR/ARHP Annual Meeting
Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin², Faye N. Hant³, Galina S. Bogatkevich⁴, Michael Roth⁵, Kim Hyun⁶, Jonathan Goldin¹, Tanjina Akter⁷, Holly Wilhalme¹, Chi-hong Tseng⁵, Shervin Assassi⁸, Dinesh Khanna⁹, Philip J. Clements⁵, Daniel E. Furst¹, Robert Elashoff¹⁰ and Richard Silver¹¹, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Department of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Biomathematics, University of California, Los Angeles, Los Angeles, CA, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: A prior study of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) demonstrated that serum concentrations of surfactant protein D (SP-D) and Krebs von…
Abstract Number: 839 • 2015 ACR/ARHP Annual Meeting
Occupational Exposures in Patients with Systemic Sclerosis Associated with Increased Frequency of Interstitial Lung Disease and Primary Pulmonary Hypertension
Brandi E. Stevens^1,2, Mary Lucas³, Thomas A. Medsger Jr.⁴ and Robyn T. Domsic⁵, ¹Division of Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) has been linked with environmental and occupational exposures. Silica and solvent exposure have the strongest known correlation with SSc. Other agents,…
Abstract Number: 1078 • 2015 ACR/ARHP Annual Meeting
CXCL4 Does Not Predict Extent or Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Michael Roth¹, Chi-hong Tseng¹, Holly LeClair², Philip J. Clements¹, Daniel E. Furst³, Maureen D Mayes⁴, Julio Charles⁵, Dinesh Khanna⁶, Robert Elashoff⁷, Shervin Assassi⁸ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Texas - Houston Medical School, Houston, TX, ⁵Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁸Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of pulmonary fibrosis (PF) by HRCT in an observational study of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].